The discovery of cisplatin is arguably one of the most important advances in cancer treatment of recent decades. The clinical use of this drug is limited by severe toxicity, notably, nephrotoxicity, neurotoxicity and emesis (Loehrer & Einhorn, 1984) . Nephrotoxicity was dose-limiting during phase I studies of cisplatin (Rossof et al., 1972; DeConti et al., 1973) . It is clinically manifest by reversible asymptomatic elevation of plasma urea and creatinine, occasional cases of frank acute renal failure necessitating dialysis, cumulative and permanent reductions in GFR (Daugaard et al., 1988b) , acute and chronic tubular injury (characterised by reduced proximal tubular salt and water reabsorption, magnesium wasting, normoglycaemic glycosuria, proteinuria, albuminuria, amino aciduria, and acute enzymuria (Daugaard et al., 1988a) ), and, acute and chronic histological changes (Gonzalez-Vitale et al., 1977) . The co-administration of intravenous fluid, mannitol, and hypertonic saline in conjunction with cisplatin has, at least partially, reduced the nephrotoxicity of this compound and these prophylactic measures are now widely used (Al-Sarraf et al., 1982) . The development of carboplatin has also reduced the nephrotoxicity of Pt-based chemotherapy since this compound causes less kidney damage than cisplatin and can be given safely without concomitant i.v. hydration (Calvert et al., 1982) . Unlike cisplatin, the tolerability of carboplatin is such that it can be administered as outpatient treatment, however, both cisplatin and carboplatin are intravenous preparations.
The ammine/amine Pt(IV) dicarboxylate class of Pt complex are promising with regard to their in vitro activity against human ovarian carcinoma cell lines both sensitive and resistant to cisplatin (Kelland et al., 1992) , and their bioavailability after oral administration in mice (Harrap et al., 1991 (Calvert et al., 1982) and in experimental models (Harrap et al., 1980) . In vivo models were used because of the potential for metabolism of ammine/amine Pt(IV) dicarboxylates and difficulties simulating this in vitro. '4C-inulin clearance, histology and renal tubular function were measured as these have been reported as sensitive tests for cytotoxic druginduced kidney damage in rodents (Goldstein et al., 1986; Jodrell et al., 1991) . Six p.o. ammine/amine Pt(IV) dicarboxylates were studied in the mouse while more detailed studies of the oral phase I agent (p.o. JM216) were undertaken in the rat.
Materials and methods
Pt complexes (Table I (w/v) and carboplatin in sterile 5% dextrose (w/v) by sonication and both were given intravenously (injection volume, 10 mg kg') via the lateral tail vein. Transient local (rats) or whole body (mice) hyperthermia (,<40'C) of less than 3 min duration was used to facilitate injections in both i.v. control and i.v. treatment groups. Ammine/amine Pt(IV) dicarboxylates were suspended in arachis oil by sonication and given by oral gavage (injection volume, 10 ml kg-'). Treatments were given as single maximum tolerated doses. The MTDs for i.v. cisplatin (mice, 7 mg kg-'; rats, 6.5 mg kg-') and i.v. carboplatin (mice, 120 mg kg-'; rats, 60 mg kg-') were as previously described (Siddik et al., 1986 (Goldstein et al., 1981; Ward et al., 1976) and when cisplatin-induced disturbances in renal function are apparent in the mouse (Jodrell et al., 1991 (Jodrell et al., 1991) . In a time-course study, mice were sacrificed at time-points ranging from 2 h to 10 days following treatment and the kidneys were removed and examined histologically. In a multiple-dose study, mice were killed 2 days after completing four consecutive weekly treatments and the kidneys were removed for histological examination. Specimens were prepared for histological examination by fixation in modified methacarn (methanol 600 ml, inhibisol 300 ml, acetic acid 100 ml) for 24 h, dehydration with ethanol, embedding in paraffin wax and staining with haematoxylin and eosin. In rats, plasma and urine samples were analysed for urea, creatinine and glucose concentrations using a Beckman Synchron AS8 automated analyser. For creatinine clearance determinations in rats, urine was collected for 24 h from 72 to 96 h and the urinary volume and urinary creatinine concentration recorded. Rats were sacrificed immediately after the urine collection (96 h) and a plasma sample taken for plasma creatinine determination. The creatinine clearance was derived by dividing the product of the urinary excretion rate (ml min 1) and urinary creatinine concentration by the plasma creatinine concentration.
Creatinine clearance was expressed as a function of body weight. Urinary N-acetyl-p-D-glucosaminidase (NAG) and leucine aminopeptidase (LAP) activity of rat urine collected from 72 to 96 h after treatment was determined using fluorometric and colorimetric methods as previously described . Urinary enzyme activity was expressed as a function of urinary creatinine concentration.
The significance of differences was tested by the t-test (Tallarida & Murray, 1987) .
Results
Mice (Table II 16 .4+1.1, P>0.1). At a dose above the MTD, JM221 (210 mg M-2) induced a small reduction (12%) in '4C-inulin clearance (14.2 ± 1.6 ml min' kg-'; P< 0.001).
Kidneys were examined histologically over a time-course from 2 h to 10 days following single MTD treatments. Renal tubular epithelial necrosis was present following i.v. cisplatin treatment at 6 and 10 days. No abnormality was found following i.v. carboplatin treatment. Following p.o. JM291, an abnormality consisting of a cortical fatty change, without necrosis, was recorded at day 6 with resolution at day 10. Oral treatment with other members of the series of ammine/ amine Pt(IV) dicarboxylates caused no histological kidney damage. In a multiple-dose experiment, kidneys were examined histologically after four consecutive weekly doses.
Renal tubular necrosis was seen following i.v. cisplatin, but no abnormality was found following multiple doses of i.v. carboplatin, p.o. JM216, p.o. JM225, p.o. JM291 and p.o. JM25 1. Plasma urea and creatinine concentrations were measured over a time-course and were not elevated after treatment with i.v. cisplatin or any other Pt complex.
Rats (Figure I and Table III) Following an MTD of i.v. cisplatin, elevations in plasma urea were first seen at 48 h, maximal at 5 days and had recovered, albeit incompletely, by 12 days (Figure 1 ). In contrast, no elevation in plasma urea was seen following i.v. carboplatin or p.o. JM216 at time points ranging from 24 h to 12 days. In more detailed studies at 4 days after treatment 46 ± 20 5.9 ± 2.8 0.13 ± 0.04 6.6 ± 0.53 (n = 7) i.v. cisplatin 30.4 ± 8.9a 188 ± 33a 0.54 ± 0.31a
3.28 ± 0.17a 7.9 ± 0.56b
36.7 ± 3.8 5.8 ± 1.3 0.14 ± 0.12 6.7 ± 0.2 (n = 3) p.o. JM216
4.4 ± 0.7 35.3 ± 4.5 5.5 ± 0.83 0.16 ± 0.13 7.1 ± 0.4 (n = 3) ap<0001; bo.00 <P<0.02. (Table III) , rats receiving i.v. cisplatin showed 5-fold elevations in plasma urea and creatinine (both P<0.001), a 10-fold reduction in creatinine clearance (0.01 <P<0.02), a 25-fold elevation in urine/plasma glucose concentration ratio (P<0.001) and a 20% increase in kidney weight (0.02> P>0.01). By comparison renal function in rats treated with i.v. carboplatin or p.o. JM216 was normal. At 4 days rats treated with i.v. cisplatin showed histological changes consistent with drug-induced injury, i.e. gross dilatation of the renal tubules, medullary tubular cast formation and necrosis of the renal tubular epithelium as manifest by pyknotic change, clearing of nuclear chromatin and cellular sloughing into the tubular lumen. In contrast, the histological appearances of rat kidney following i.v. carboplatin or p.o. JM216 treatment were within normal limits. Urinary Nacetyl-p-glucosaminidase (NAG) activity, urinary leucine aminopeptidase (LAP) activity and urinary output 72 to 96 h following treatment were similar in control and treatment groups. 
Discussion
We have studied the nephrotoxicity of a series of six p.o. ammine/amine Pt(IV) dicarboxylate complexes in rodents with variations in chemical structure at the (i) axial dicarboxylate (formato, acetato, butyrato or ethylcarbamate substituents), (ii) amine (cyclopentylamine or cyclohexylamine substituents), and (iii) leaving group (dichloro of oxalato substituents) positions. These compounds have been identified as potential candidates for clinical testing as orally active Pt-based drugs (Harrap et al., 1991) .
These studies of nephrotoxicity in rodents included i.v. cisplatin and i.v. carboplatin as controls. The effects of i.v. cisplatin were similar to those previously described (Harrap et al., 1980; Jodrell et al., 1991; Ward et al., 1976) in that this agent caused proteinuria, glycosuria, reduced GFR and histological kidney damage in the mouse, and elevated plasma creatinine, elevated plasma urea, reduced creatinine clearance, urinary glucose wasting, increased kidney weight and renal histological damage in the rat. By comparison, i.v. carboplatin effected neither renal function nor kidney histology in either species. These findings concur with their relative clinical nephrotoxicity since cisplatin can cause severe and irreversible damage to renal function in man (Daugaard et al., 1988) while the toxicity of carboplatin is confined to the reductions in GFR after high-dose therapy (Gore et al., 1987) and the possibility of cumulative reductions in GFR in some patient groups (Sleijfer et al., 1989; Mason et al., 1990) .
In mice, single MTD treatments of six p.o. ammine/amine Pt(IV) dicarboxylates caused neither proteinuria, glycosuria nor major histological changes. Transient cortical fatty change, without necrosis, was recorded following treatment with one oral compound (JM291). GFR estimates in control mice were similar to reported values (Jodrell et al., 1991) and neither p.o. JM216 nor p.o. JM221 treatment at the MTD caused reductions in this parameter. Above the MTD, p.o. JM221 caused a small reduction in GFR, possibly in keeping with reports of reductions in GFR during high-dose carboplatin therapy (Gore et al., 1987) . In rats, the time-course of elevated plasma urea following i.v. cisplatin treatment was consistent with previous descriptions (Ward et al., 1976) , however, plasma urea was normal following treatment with the oral phase I candidate (p.o. JM216) at time points ranging from 24 h to 10 days. Creatinine clearance values in control rats were similar to reference values (Altman & Dittmer, 1974) (Jodrell et al., 1991) , however, the lack of cumulative damage of p.o. ammine/amine Pt(IV) dicarboxylates studies has not been confirmed by studies of renal function to date. In mice, following single doses of i.v. cisplatin, plasma creatinine and urea were within the control range. This is consistent with previous suggestions of these being of poor utility for screening purposes because they are insensitive manifestations of Pt-induced kidney damage, both in this species (Jodrell et al., 1991) and in man (Daugaard et al., 1988b) . Similarly in rats, we found neither urinary NAG nor LAP activity elevated following cisplatin treatment.
In conclusion, this series of p.o. ammine/amine Pt(IV) dicarboxylates are not toxic to the kidney in rodents at maximum tolerated doses and on this basis are suitable for development as oral Pt outpatient therapy. Their lack of nephrotoxicity was comparable to i.v. carboplatin suggesting that the co-administration of i.v. hydration, such as is necessary with i.v. cisplatin, may not be required. Abbreviations: cisplatin, cis-diamminedichloroplatinum(II); carboplatin, cis-diamminecyclobutanedicarboxylatoplatinum(II); GFR, glomerular filtration rate; h, hour; i.v., intravenously administered; p.o., orally administered; MTD, maximum tolerated dose; Pt, platinum.
